Marco Annas

Women in focus: Focus on heart health ❤️ and identify cardiovascular risk early 🔍 As part of my Austrian tour 🇦🇹 on women's health, I had a very insightful conversation today with Beate Scheiber, health spokesperson in the Tyrolean state parliament. Our meeting focused on the important topic of cardiovascular disease in women 👩‍⚕️. Women are often at increased risk of cardiovascular disease and it is crucial to be aware of your own cholesterol levels. Beate Scheiber emphasized the need for an incentive system to motivate people to get regular check-ups 🩺. The free preventive medical examination is the ideal tool for identifying risks early and taking preventive measures. By raising awareness of these issues, we can make a significant contribution to improving women's health. I look forward to working with committed partners 🤝 like Beate Scheiber to further raise awareness of women's health and implement concrete measures. #WomenHealth #CardioVascularDiseases #ASCVD #HealthPolicy #ReimaginingMedicine Prof. Dr. Ludwig Sabine, MSc., MA Cornelia Hagele Viktoria Kapferer Agnes Schöchl Daniela Gutschi Maria Rauch-Kallat Naghme Dr.Kamaleyan-Schmied Michael S. Gudrun Kreutner-Reisinger

99

3 Kommentare

What was the biggest career risk you ever took?   On May 5, Bayer had the privilege of hosting this year’s The LAGRANT Foundation (TLF) dinner at Vinateria in Harlem, NY. Career risks – and opportunities – were among the topics we discussed during one of my favorite nights of the year, where we bring together experienced professionals and #NextGenTalent in the advertising, marketing, digital, media and PR space.   This year, TLF provided scholarships to 50 undergraduate and graduate ethnic minority students who are pursuing careers in the fields of advertising, marketing or public relations.    Alongside my fellow panelists, Sarita T. Finnie and Glenniss Richards, MBA, we shared our personal career stories and advice with this year’s scholarship recipients. A few takeaways that stuck with me: 💡 Be a sponge: raise your hand, get new experience and embrace opportunities. 💡 Be authentic. 💡 Be a learner and be inquisitive. 💡 Be bold in sharing your ideas. 💡 Be an advocate for yourself.   As always, this year’s students demonstrated drive and curiosity, reinforcing my belief in the transformative power of education and mentorship in one’s career journey. Guiding the next generation isn’t just about imparting knowledge... it’s about igniting their potential and empowering them to soar. 💫   Learn more about TLF and support their mission here: https://lnkd.in/e9wm-DHZ   #TeamBayer #Talent #DEI   Kim Hunter, Jessica Shih, Erin Glarner, CMP, Shari Kurzrok Schnall, David Janes, Kim Albataew, Andrianna Guo, PharmD, MBA, Ayana Woods, Ben DeLand, Rafael Peralta, MBA, MPH, Eleanor Byars

234

5 Kommentare

At Bayer, we are always in favor of greater investment in transformative therapies. This is essential to advance patient care and position Germany as a leader in biotech. The Berlin Center for Gene and Cell Therapies is a prime example of this effort. As a flagship project, it represents a one-of-a-kind public-private partnership between Charité - Universitätsmedizin Berlin – Universitätsmedizin Berlin and Bayer, with support from the German Federal Government / Federal Press Office – German Government and the State of Berlin (Land Berlin). Gene and cell therapies, often referred to as "living drugs", are among the most groundbreaking advancements in healthcare. They offer personalized treatments for cancer, autoimmune diseases, neurodegenerative disorders, and rare genetic conditions, transforming previously untreatable diseases. To accelerate the translation of basic research into patient benefits, the Center will be established on the Bayer campus at Berlin Nordhafen. It aims to create a top-tier biotech innovation ecosystem, gathering start-ups and partners, supported by the Bundesministerium für Bildung und Forschung. The Center will feature an incubator with state-of-the-art labs, offices, common areas, and a GMP-certified (Good Manufacturing Practice) development and production area, accommodating 15 to 20 start-ups and 300 to 350 employees. Bringing together the right stakeholders was key to aligning industry interests and leveraging research institutions with financial support. By fostering collaboration, we have laid a crucial foundation for Germany's long-term strategy in biotech innovation. This project bridges the gap between research and market-ready products, positioning Germany as a future global leader in biotech innovation alongside the USA and China. The integration of university expertise and a start-up atmosphere will drive this innovative environment, set to start operating in 2028. We extend our gratitude to all our partners for their invaluable support in making this vision a reality. You can find the press release here: https://lnkd.in/gpzMqHx9 #Sustainability #Innovation #CellTherapy #GeneTherapy #PublicPrivatePartnership

41

This #WorldDiabetesDay coincides with a significant leap forward for the Changing Diabetes® in Children programme, our public-private partnership supporting children and youth with type 1 diabetes. Today marks the official launch in China, where the number of type 1 diabetes in children and adolescents ranks fourth globally.   We’re not starting from scratch. We’re bringing: 🔎15 years of programme insights 🌍Experiences from over 30 countries 🤝Collaboration with world-class global and local partners   Launching in China isn't just a milestone—it's a springboard that propels us closer to our ambitious goal of reaching 100,000 children globally by 2030.   How can we improve access to diabetes care for children, particularly in underserved communities? Find out more about our impact: https://bit.ly/4hGo7Qs   #NovoNordisk #DrivingChange #WDD2024 #WorldDiabetesDay #HealthEquity

96

3 Kommentare

Fresenius Kabi, a subsidiary of Fresenius SE, has announced the availability of Tyenne®, the first tocilizumab biosimilar in the U.S. This biosimilar, 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗯𝘆 𝘁𝗵𝗲 𝗙𝗗𝗔 𝗳𝗼𝗿 𝗯𝗼𝘁𝗵 𝗶𝗻𝘁𝗿𝗮𝘃𝗲𝗻𝗼𝘂𝘀 𝗮𝗻𝗱 𝘀𝘂𝗯𝗰𝘂𝘁𝗮𝗻𝗲𝗼𝘂𝘀 𝘂𝘀𝗲, offers a more accessible and affordable treatment option for patients with chronic autoimmune diseases. Tyenne®'s launch contributes significantly to Fresenius' (Bio)Pharma platform, aligning with its #FutureFresenius strategy. 𝗧𝘆𝗲𝗻𝗻𝗲® 𝗺𝗮𝗿𝗸𝘀 𝗙𝗿𝗲𝘀𝗲𝗻𝗶𝘂𝘀' 𝘁𝗵𝗶𝗿𝗱 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗶𝗻 𝘁𝗵𝗲 𝗨.𝗦. 𝗮𝗻𝗱 𝘀𝗲𝗰𝗼𝗻𝗱 𝗶𝗻 𝗶𝘁𝘀 𝗶𝗺𝗺𝘂𝗻𝗼𝗹𝗼𝗴𝘆 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼. 𝗜𝘁 𝘁𝗿𝗲𝗮𝘁𝘀 𝘃𝗮𝗿𝗶𝗼𝘂𝘀 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝘀𝘂𝗰𝗵 𝗮𝘀 𝗿𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗶𝗱 𝗮𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀 𝗮𝗻𝗱 𝘀𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝗷𝘂𝘃𝗲𝗻𝗶𝗹𝗲 𝗶𝗱𝗶𝗼𝗽𝗮𝘁𝗵𝗶𝗰 𝗮𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀. Fresenius Kabi's CEO sees Tyenne® as a game-changer in the U.S. healthcare landscape, emphasizing their commitment to expanding patient access to advanced biopharmaceuticals. The company's support program aims to assist healthcare professionals and patients, ensuring broader access to treatment options. 𝗔𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹𝗹𝘆, 𝗙𝗿𝗲𝘀𝗲𝗻𝗶𝘂𝘀 𝗞𝗮𝗯𝗶 𝗵𝗮𝘀 𝗮 𝗿𝗼𝗯𝘂𝘀𝘁 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝗼𝗳 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗮𝗻𝗱 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗶𝗻 𝗹𝗮𝘁𝗲-𝘀𝘁𝗮𝗴𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁, 𝗿𝗲𝗳𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗶𝘁𝘀 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻. Fresenius' overarching strategy, #FutureFresenius, focuses on becoming a leading therapy-focused company. #marketintelligence #competitiveintelligence #pharmaceutical #marketsmind #tocilizumab #freseniuskabi

20

1 Kommentar

A staggering four billion people lack access to essential healthcare. The Access to Medicine Foundation, under Jaysree's leadership, has a tremendous impact on addressing this huge gap by advocating for systemic change to tackle health inequities. At Bayer, we recognize the urgent need to do more for patients in underserved communities around the world, particularly those residing in low- and middle-income countries. In this video, I provide insights into how we take actionable steps to expand access to those who need it most. These changes have led to Bayer advancing from #16 to #9 on the ATM Index over the past few years. Our newly established Global Health Unit, which has a strong focus on the needs of geographies where Bayer | Pharmaceuticals has no presence, is another testament to our steadfast commitment to continuously advancing access to our entire portfolio for even more people around the globe. #teamBayer #SDG3 #AccessToMedicine

37

I endorse EFPIA's call for EU leaders to enhance collaboration with industry leaders and the creation of an EU Office for Life Sciences within the European Commission to reestablish Europe as a life sciences leader. Amidst political changes and mounting public health and climate challenges, Europe must reclaim its status as a premier location for research, skills, and private investment. The pharmaceutical industry in Europe faces intense global competition. Amidst the rapid growth of countries like China and Korea and the US, the latter of which saw its share of global R&D rising from €2 billion a year to €25 billion a year – more than Europe in 20 years, highlight the urgent need for action. Europe needs an innovation-driven ecosystem where biotech and pharmaceutical companies collaborate, supported by more resilient and sustainable European health systems, and investments in scientific advancement. This means viewing health expenditure as a future investment, and strategically funding infrastructure, prevention and digitalization to manage challenges effectively. https://lnkd.in/gc5F749D #teambayer

40

#Disparagement will be the hot topic in #pharma and #lifesciences companies this week, after the European Commission handed down a landmark €463 million fine for targeting a rival’s reputation. So what is “disparagement” in political communication? It’s the thin line where competitive tactics risk becoming anticompetitive practices, especially when a company with market power actively undermines a competitor’s reputation among stakeholders. In the given case, this involved influencing doctors, pricing authorities, and reimbursement officials against a rival product — a novel stance by the Commission that will resonate across the industry. For companies navigating the complex world of public affairs, a #healthcheck of your political communication strategies is a smart step to take now. Ensuring that communications remain focused on merit-based competition is essential for protecting both reputation and compliance in a highly regulated space. #Pharma #LifeSciences #CompetitionLaw #PublicAffairs #EUCompliance https://lnkd.in/ewsw_7nQ

5

❓❓❓Did you know that women are seven times more likely to be misdiagnosed or discharged from the emergency room for cardiovascular diseases than men? This means that women are twice as likely to die from serious cardiovascular diseases as men 💔❤️‍🩹 On the occasion of #EuropeDay 🇪🇺 today, I would like to invite you to a special event at Club alpha (Hildegard Burjan Institut) which I will be hosting together with Pia-Maria Santer. Under the motto "EU elections: Strengthening through diversity - Paths to equality in the EU", we will discuss how diversity and equality can strengthen the European Union and place a very special focus on the topic of women's health in the European Union. 📅 Date: May 27, 2024 🕒 Time: 7 p.m. 📍 Location: Club alpha, Stubenbastei 12/14, 1010 Vienna 🎤 Our panel discussion with Kasia Greco (ÖVP), Petra Steger (FPÖ) tbc, Ines Vukajlović (Greens), Dr. Arabel Bernecker-Thiel (NEOS) and Sophia Reisecker (SPÖ) will shed light on the challenges and opportunities of the 2024 EU elections, particularly with regard to equality and diversity. Our experts will share valuable insights and discuss practical approaches to achieving these important goals. 👩‍⚕️ The event will focus particularly on women's health. The report "Closing the Women's Health Gap“ published by the World Economic Forum and McKinsey & Company in January 2024, highlights the significant health disparities women face. Despite significant research efforts and investments, the report shows that there is a lack of attention for many women-specific diseases. Further improvements in diagnosis and treatment protocols that take gender differences into account are needed to reduce these disparities and improve health outcomes for women in Europe. https://lnkd.in/d7vnxqPR Don't miss the opportunity to be part of this important dialogue. We look forward to lively participation and exciting discussions. 🌍✨ Register now! https://lnkd.in/d-85iPQp #EuropeDay #WomensHealth #EUelections2024

80

4 Kommentare

Based on OECD report, trade and market openness has historically gone hand-in-hand with better economic performance in countries at all levels of development, creating new opportunities for workers, consumers and firms around the globe and helping to lift millions out of poverty. Trade openness also benefits firms, by giving producers access to bigger markets, allowing them to increase the scale of their production, and encouraging market competition and innovation. Firms that export tend to be more productive than those that do not. Trade helps to reallocate resources to the sectors and areas where they can be most efficient. This is one of the key gains from trade, but also one of its costs. Not all of the gains from trade are immediate, and not every worker benefits. Losses can be sharp and concentrated on individuals, often those with the least capacity to adjust on their own. In the face of these concerns, governments can feel pressure to implement protectionist policies and measures – including tariffs, quotas and various forms of subsidies – as a way of 'saving' domestic jobs and enterprises. However, protection penalizes those it aims to protect: jobs retained solely by protection are unlikely to be sustainable, nor to generate other jobs; protecting specific jobs or firms is a costly way of helping relatively few people, with costs (increasing over time) for jobs in other sectors, and for low income households facing higher prices.  https://lnkd.in/gbkq_t38

12

Family planning isn't merely a choice; it's the cornerstone of women's empowerment, a key driver for reducing poverty, and a critical factor in achieving sustainable development. It unlocks tremendous potential on a global scale. As a leader in women's health, Bayer deeply understands the transformative power of investing in contraception. It's a direct path to realizing the United Nations' SDGs. We've hence set an ambitious goal for ourselves: fulfilling the need of 100 million women in low-and middle-income countries with modern contraception by 2030. By co-creating solutions tailor-made for local needs with various partners across different healthcare ecosystems globally, we're empowering young people with knowledge, systemically removing barriers to care with innovative solutions, and enabling access to modern contraception. Reaching 46 million women in 2023 is a powerful testament to the strength of these partnerships. This World Contraception Day, and every day, our commitment to gender equity remains unwavering.   #WCD2024 #WorldContraceptionDay2024

110

2 Kommentare

Excellent momentum forward

10

1 Kommentar

It is with immense pride that I share that Bayer has ranked in the Top Ten of the Access to Medicine Index (ATMI) 2024. For the second consecutive time, we again score above average in all three Technical Areas: Governance of Access, R&D and Product Delivery. This is an important reflection of how #TeamBayer walks the talk when it comes to our mission #HealthforAll, #HungerforNone.   In 2019 we set ourselves the ambitious goal of being amongst the Top Ten of the 20 largest pharmaceutical companies, in line with our #ESG strategy. Being ranked in the Top Ten again is a strong acknowledgment of the impact our work has on the lives of millions of patients in low-and middle-income countries (#LMICs).   And we do not rest. This year, Bayer | Pharmaceuticals launched a Global Health Unit (GHU) to further expand access to medicines to underserved communities in LMICs where Bayer has no or limited presence. In the area of Family Planning, 46 million women were reached with modern contraception in 2023 which aligns with the goal of our pharmaceuticals division to help provide 100 million women in LMICs with access to this yearly by 2030. Family planning is the bedrock of women’s empowerment and a major factor for reducing poverty and achieving #sustainability goals. The Access to Medicine Foundation praised Bayer’s initiatives to improve access to its contraceptives, and for measuring and reporting patient reach.   None of this would be possible without the passion and hard work of our people. I am deeply proud of the team’s unwavering commitment to support vulnerable populations around the world. I would also like to thank the Access to Medicine Foundation for stimulating our industry to keep raising the bar. We value their recommendations for further enhancing our access to medicine strategy, as these insights align with the objectives we set when establishing the GHU. As the GHU matures, we aim to grow our ability to expand, track and report patient reach for an even broader range of products.   It takes a united effort to move the needle forward, and I am confident in our future! Read the full report here: https://lnkd.in/er8sfCZA #SDGs #HealthEquity #EmpoweringWomen #FamilyPlanning #AccessToMedicine  

151

7 Kommentare

With rising demand and an ageing population, European healthcare systems are under strain. In the second article in our series on addressing Europe’s healthcare challenges, The Parliament and AbbVie explore how innovation can unlock capacity and deliver better outcomes for patients living with Parkinson’s. https://lnkd.in/dsXNxDyu

22

Did you know? Bacteria, viruses and other microorganisms are increasingly surviving the medicines intended to treat them. It's called antimicrobial resistance, or AMR, and it's a major health threat.   Across Teva's operations and supply chain, we’re addressing #AMR in many ways. We piloted a program in Germany to get messages to people right when they picked up their antibiotics from the pharmacy or clinic to help them learn about ways to prevent AMR. So far we sent digital messages with these tips to:   🏥 ~11,000 pharmacies 🩺 ~65,000 healthcare professionals 🌐 ~275,000 patients   As a company that makes antimicrobial medicines, we want to make sure they work. And if we all take steps to address AMR, like prescribing and using antibiotics correctly, we can contribute to healthy people and a healthy planet, which are essential for a #HealthyFuture.   #AntimicrobialResistance

5

🌍 An ageing population combined with rising demand is straining #healthcare systems. Explore how innovation is redefining care for #Parkinson’s patients in Europe. This article by Parliament Magazine and AbbVie delves into transformative technologies and approaches that could boost capacity and improve outcomes for #patients and everyone supporting them. 💡 Parkinson's disease, rapidly becoming Europe’s 3rd leading cause of disability and premature death, highlights disparities in care access. Gain insights from experts on how holistic solutions and #EUPharmaceuticalStrategy are vital for driving change in patient care. 📖 Check out this compelling read that emphasizes rethinking care pathways and utilizing new solutions for enhanced #neurological care: https://lnkd.in/dyqFKqxy

7

The European Association for the Study of Diabetes e.V. (EASD) Annual Meeting provides another opportunity to showcase the latest developments in type-2 diabetes and interconnected metabolic diseases, and how these will shape the future of patient care. Obesity is a complex, chronic, relapsing disease which is linked to over 200 comorbidities, including cardiometabolic diseases. It represents a global epidemic, and approximately 58% of people living with one or more overweight/obesity comorbidity have type-2 diabetes. At AstraZeneca we’re building on our commitment in type-2 diabetes and tapping into our legacy of expertise in cardiovascular and kidney diseases to uncover novel metabolic disease pathways in obesity that could go beyond short-term weight loss, deliver weight management, address cardiometabolic risk and protect organs. Learn more: https://lnkd.in/eeWtMJxp #EASD2024

35

2 Kommentare

What are the leadership capabilities for a sustainable future?   Explore the just released 2024 UCB-SBSEM Business and Society Symposium report ‘Purpose in action: Leadership towards sustainable transition, in mindset and practice’, and delve into the critical ways leadership needs to change and the importance of multi-stakeholder collaboration for building a sustainable future. 👉 https://lnkd.in/etTKfEk2 Drawing on insights from keynote speakers, case study representatives and participants at the Symposium, the report highlights:    ⚡ Essential leadership characteristics and skills, including courage, boldness, and authenticity,    🚩 The challenges organizations are facing, including rigid hierarchies and having difficult conversations,    ✅ The concrete solutions required to transform the way we work and build a more equitable society, respectful of planetary boundaries.    The diverse and forward-looking insights are an important reminder that meaningful change relies on collective engagement of individuals who dare to act differently.    As mentioned during the meeting, we are all leaders and we all need to work together to transform organizations, transform the economy and prepare a better world for the generations to come.   You can read this report to take leadership for a sustainable future into your own hands and enhance your capacity to collaborate with courage, creativity and openness.   Thanks to everyone who contributed to the success of the Symposium and the development of this report that I am happy to share with you today! Estelle Cantillon Valérie Julien Gresin Anushay A. Imogen Davidson Charline Desmecht Rafaële Rikir Chiara Montecucco #teamUCB #sustainability #fitforfuture #leadership

87

1 Kommentar